Health Care

Cancer is one of the most expensive conditions to treat, driving about 20 percent of a company's healthcare spend.

Shares of Tesaro soared early Monday after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker.

Glaxo plans to pay $75 per share for Tesaro.

Stocks are wobbling ahead of the highly-anticipating trade meeting between President Donald Trump and President Xi Jinping of China.

After repeated food poisoning outbreaks linked to romaine lettuce, the produce industry is confronting the failure of its own safety measures in preventing contaminations.

German pharmaceutical giant Bayer AG says it's cutting 12,000 jobs worldwide as it seeks to reduce costs.

Australian Army veteran Wolfgang Neszpor was stunned when he heard his recently repaired shoulder squeak.

The $69 billion mega-merger was finalized on Wednesday.

CVS expects the deal to save as much as $750 million over the course of two years.

Dubbed “Amazon Comprehend Medical,” the software can automatically pull relevant information from medical notes, audio transcripts and patient records.

The health insurer also reiterated its adjusted earnings forecast of about $14.40 per share for the year 2018.

The head of the Food and Drug Administration's device center was adamant: the U.S. would never cut corners to speed up product approvals.

The latest on developments in financial markets (all times local): 9:35 a.m.

When Polly Varnado's 9-year-old daughter was diagnosed with Type 1 diabetes, it didn't take long for the family to hear about insulin pumps.

Dr. Jeffrey Shuren was adamant: The United States would never cut corners to fast-track the approval of medical devices.

Roughly 3,000 medical devices enter the U.S. market every year through a system that generally requires little or no patient testing to verify safety and effectiveness.

Desperate for relief after years of agony, Jim Taft listened intently as his pain management doctor described a medical device that could change his life.